The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Articles|April 2, 2024
- Pharmaceutical Technology, April 2024
- Volume 48
- Issue 4
- Pages: 12
Dual Shaft Mixers Line
Author(s)Pharmaceutical Technology Editors
The ROSS line of Dual Shaft Mixers are robust, versatile systems with enough power to batch dispersions, suspensions, and emulsions with viscosities up to several hundred thousand centipoise.
The ROSS line of Dual Shaft Mixers are robust, versatile systems with enough power to batch dispersions, suspensions, and emulsions with viscosities up to several hundred thousand centipoise. The custom-built ROSS FDA-3500 has a maximum working capacity of 3500 gallons, a two-zone stainless-steel dimpled jacket for heating/cooling, a 4-inch pneumatic discharge valve, and an explosion-proof load cell system rated for up to 20,000 lbs.
This multi-agitator system is equipped with independently controlled drives and is designed to efficiently produce good turnover and impart shear to a viscous batch. Powered by a 300 HP TEFC inverter duty motor, the High Speed Disperser runs at tip speeds up to 5000 ft. per minute, inducing high shear forces. Meanwhile, the 60 HP Three-Wing Helical Anchor Agitator feeds product towards the disperser blade and ensures that the mixture is constantly in motion. Teflon scrapers on the anchor wipe materials from the vessel wall, enhancing heat transfer from the jacket.
Articles in this issue
over 2 years ago
The Growing Future of Drug Manufacturingover 2 years ago
Steps Towards Demystifying Risk-Based Decision Makingover 2 years ago
Development of Mini-Tablet and Multi-Unit Pellet Systemsover 2 years ago
Innovations in Prefilled Biologicsover 2 years ago
Testing the Limits of Extractables and Leachablesover 2 years ago
Making Lifecycle Management More Efficient in Europeover 2 years ago
Taking Full Advantage of Service Providersover 2 years ago
Looking at the Potential Impact of JCA on Pharmaover 2 years ago
Streamlining Variationsover 2 years ago
May I Present the NeoantigenRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.